Phillip A. Sharp — Co-Founder, Director & Member of the Scientific Advisory Board at Alnylam Pharmaceuticals

Dr. Phillip A. Sharp, also known as Phil, Ph.D., serves as the President of American Association for the Advancement of Science. Dr. Sharp co-founded Alnylam Pharmaceuticals, Inc. in 2002. He Co-founded Biogen Inc. (formerly Biogen Idec Inc.) in 1978. He co-founded Magen BioSciences, Inc. (formerly PPD Dermatology, Inc.) in 2006. He has been Institute Professor of Center for Cancer Research, Massachusetts Institute of Technology since 1999. He joined the Center for Cancer Research at MIT in 1974 and served as its Director of the Center for Cancer Research from 1985 to 1991. From 1991 to 1999, He was Salvador E. Luria Professor and Head of the Department of Biology of Center for Cancer Research (now the Koch Institute) at MIT. He serves as the Chairman of Scientific Advisory Board of Fidelity Biosciences. He served as a Co-Chairman of Scientific Strategy and Advisory Group of Alnylam Pharmaceuticals, Inc. since October 6, 2005. He has been a Director at Alnylam Pharmaceuticals, Inc. since June 2002 and serves as its Member of Scientific Advisory Board. He serves as a Member of Scientific Advisory Board at F-Prime Capital Partners. He has been a Director of Syros Pharmaceuticals, Inc. since December 2012 and has been its Member of Scientific Advisory Board since April 2013. He serves as a Director at McGovern Institute. He serves as a Director of Vir Biotechnology, Inc. He serves as a Director of Broad Institute of MIT and Harvard. He serves as Director and Member of Strategic Advisory Board of Longwood Founders Management, LLC. He serves as a Member of Advisory Group at MIT Center for Biomedical Innovation and Member of Editorial Advisory Board of Xconomy, Inc. Dr. Sharp served as a Member of Scientific Advisory Committee of Ludwig Institute for Cancer Research Ltd. He serves as a Member of Scientific Advisory Board at Verastem, Inc. He serves as a Director of Alfred P. Sloan Foundation. He serves as a Member of Medical Advisory Board of Gairdner Foundation. He was a Founding Director of the McGovern Institute for Brain Research, Massachusetts Institute of Technology from March 2000 to 2004. He served as a Director of Biogen Idec Ma Inc. since 1982 and Biogen Inc. from 1982 to July 2009. He served as a Member of Scientific Advisory Board of Sirtris Pharmaceuticals, Inc. He served as a Director at Biogen MA Inc. since 1982. He served as a Director and Member of Scientific Advisory Board at PPD Dermatology, Inc. His long list of service includes the presidency of the AAAS in 2013 and Chair of the Scientific Advisory Committee, SU2C Project, AACR. He is a Member of the National Academy of Sciences, the American Academy of Arts and Sciences and the Institute of Medicine. He is a Member of the American Philosophical Society and the Royal Society, UK. His research interests centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing. His landmark work in 1977 provided one of the first indications of the startling phenomenon of ???discontinuous genes??? in mammalian cells. He received the Nobel Prize for Physiology or Medicine in 1993, for his work in molecular biology and was a National Medal of Science recipient in 2006. He has authored over 350 scientific papers. His work has earned him numerous cancer research awards and presidential and national scientific board appointments. He is the recipient of the 2004 National Medal of Science and the 2006 inaugural Double Helix Medal from CSHL. Dr. Sharp received a BA from Union College in Kentucky and a Ph.D. in Chemistry from University of Illinois.